A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis Academic Article uri icon

Overview

MeSH Major

  • Diabetes Complications
  • Gastroparesis
  • Macrocyclic Compounds
  • Receptors, Ghrelin

abstract

  • TZP-102 for 28 days, at doses of 10-40 mg once daily, was well-tolerated and resulted in a reduction in symptoms of gastroparesis. The lack of correlation between symptom improvement and gastric emptying change is consistent with previous studies in diabetic gastroparesis, and emphasizes the value of patient-defined outcomes in determining therapeutic benefit.

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/nmo.12064

PubMed ID

  • 23279217

Additional Document Info

start page

  • e140

end page

  • 50

volume

  • 25

number

  • 2